247 related articles for article (PubMed ID: 32414635)
1. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
2. Estimation of manufacturing development costs of cell-based therapies: a feasibility study.
Ten Ham RMT; Nievaart JC; Hoekman J; Cooper RS; Frederix GWJ; Leufkens HGM; Klungel OH; Ovelgönne H; Hoefnagel MHN; Turner ML; Mountford JC
Cytotherapy; 2021 Aug; 23(8):730-739. PubMed ID: 33593688
[TBL] [Abstract][Full Text] [Related]
3. A roadmap for cost-of-goods planning to guide economic production of cell therapy products.
Lipsitz YY; Milligan WD; Fitzpatrick I; Stalmeijer E; Farid SS; Tan KY; Smith D; Perry R; Carmen J; Chen A; Mooney C; Fink J
Cytotherapy; 2017 Dec; 19(12):1383-1391. PubMed ID: 28935190
[TBL] [Abstract][Full Text] [Related]
4. Towards a common framework for defining ancillary material quality across the development spectrum.
Ball O; Zylberberg C
Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
[TBL] [Abstract][Full Text] [Related]
5. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P
Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061
[TBL] [Abstract][Full Text] [Related]
6. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
Harrison RP; Rafiq QA; Medcalf N
Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
[TBL] [Abstract][Full Text] [Related]
7. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.
Wang K; Liu Y; Li J; Wang B; Bishop R; White C; Das A; Levine AD; Ho L; Levine BL; Fesnak AD
Cytotherapy; 2019 Oct; 21(10):1081-1093. PubMed ID: 31445816
[TBL] [Abstract][Full Text] [Related]
8. Putting a price tag on novel autologous cellular therapies.
Abou-El-Enein M; Bauer G; Medcalf N; Volk HD; Reinke P
Cytotherapy; 2016 Aug; 18(8):1056-1061. PubMed ID: 27288308
[TBL] [Abstract][Full Text] [Related]
9. Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation.
Lam C; Meinert E; Yang A; Cui Z
Cytotherapy; 2021 May; 23(5):433-451. PubMed ID: 33674239
[TBL] [Abstract][Full Text] [Related]
10. Regulation of advanced therapy medicinal products in Europe and the role of academia.
Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
[TBL] [Abstract][Full Text] [Related]
11. Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting.
Iancu EM; Kandalaft LE
Curr Opin Biotechnol; 2020 Oct; 65():233-241. PubMed ID: 32663771
[TBL] [Abstract][Full Text] [Related]
12. Variation in patient routine costliness in U.S. psychiatric facilities.
Cromwell J; Drozd EM; Gage B; Maier J; Richter E; Goldman HH
J Ment Health Policy Econ; 2005 Mar; 8(1):15-28. PubMed ID: 15870482
[TBL] [Abstract][Full Text] [Related]
13. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
Sutherland V; Buffo MJ; Whiteside TL
Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
[TBL] [Abstract][Full Text] [Related]
14. Vector production in an academic environment: a tool to assess production costs.
Boeke A; Doumas P; Reeves L; McClurg K; Bischof D; Sego L; Auberry A; Tatikonda M; Cornetta K
Hum Gene Ther Methods; 2013 Feb; 24(1):49-57. PubMed ID: 23360377
[TBL] [Abstract][Full Text] [Related]
15. Modeling biological and economic uncertainty on cell therapy manufacturing: the choice of culture media supplementation.
Bandeiras C; Cabral JM; Finkelstein SN; Ferreira FC
Regen Med; 2018 Dec; 13(8):917-933. PubMed ID: 30488770
[TBL] [Abstract][Full Text] [Related]
16. Developing a Blockchain-Based Supply Chain System for Advanced Therapies: Protocol for a Feasibility Study.
Lam C; van Velthoven MH; Meinert E
JMIR Res Protoc; 2020 Dec; 9(12):e17005. PubMed ID: 33315020
[TBL] [Abstract][Full Text] [Related]
17. Towards Automated Manufacturing for Cell Therapies.
Smith D; Heathman TRJ; Klarer A; LeBlon C; Tada Y; Hampson B
Curr Hematol Malig Rep; 2019 Aug; 14(4):278-285. PubMed ID: 31254154
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods.
Harrison RP; Zylberberg E; Ellison S; Levine BL
Cytotherapy; 2019 Feb; 21(2):224-233. PubMed ID: 30770285
[TBL] [Abstract][Full Text] [Related]
19. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.
Shukla V; Seoane-Vazquez E; Fawaz S; Brown L; Rodriguez-Monguio R
Hum Gene Ther Clin Dev; 2019 Sep; 30(3):102-113. PubMed ID: 30968714
[No Abstract] [Full Text] [Related]
20. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
Hourd P; Ginty P; Chandra A; Williams DJ
Cytotherapy; 2014 Aug; 16(8):1033-47. PubMed ID: 24856894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
